NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
08 February 2025
Name: | GENETIC TECHNOLOGIES LIMITED (GTG) | ||||||||||||||||||
ISIN: | AU000000GTG7 | ||||||||||||||||||
Date of Listing: | 30 July 1987 | ||||||||||||||||||
Former Names: |
|
Stock Exchange Status: (updated daily)
This entity is currently suspended from quotation on the Australian Securities Exchange and its securities cannot be traded on-market.Legal Status: (updated monthly)
ACN: 009 212 328ABN: 17 009 212 328
Registration Date: 05 January 1987
Capital Gains Tax (CGT) Status: (updated at least quarterly)
The securities in this entity, in our opinion, are of little or no value. We have made that assessment by reference to the circumstances leading to a suspension and/or delisting, the length of a suspension, share trading history and last on-market share price, most recent financial and cash flow statements, prospects (including likelihood of re-financing), and other factors including in particular whether the entity is in external administration. If you are seeking to crystallise a capital loss on your securities, that process can be easily and quickly initiated at our online Worthless Shares facility here: https://www.delisted.com.au/sell-worthless-and-other-securities/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
FROM | TO | |
GENETIC TECHNOLOGIES LIMITED | 04/09/2000 | |
DUKETON GOLDFIELDS LIMITED | 01/11/1999 | 04/09/2000 |
DUKETON GOLDFIELDS NL | 20/03/1995 | 01/11/1999 |
CONSOLIDATED VICTORIAN MINES NL | 20/02/1992 | 20/03/1995 |
CONSOLIDATED VICTORIAN GOLD MINES NL | 22/08/1991 | 20/02/1992 |
CONCORD MINING NL | 22/08/1991 |
Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail
Expand this box to read and print
The company's Voluntary Administrators have called a reconvened second creditors' meeting on 12 February 2025. The meeting will decide whether to execute a DOCA, end administration, or wind up the company. The Administrators believe it is in creditors' interests. | 05/02/2025 |
The entities suspended for over three months failed periodic reports, the oldest outstanding report deadline, and their 2 year deadline for trading plans. If not met, they will be removed from the official list, usually after the first trading day. | 22/01/2025 |
On 15 January 2025, Genetic Technologies Limited entered into a conditional agreement to sell its direct to consumer AffinityDNA and EasyDNA businesses to Endeavor DNA, Inc. On Saturday, 18 January 2025 the sale of the AffinityDNA and EasyDNA businesses completed. GTG has also granted Endeavor an option to purchase two of its subsidiaries that employ persons involved in conducting the businesses, exercisable by Endeavor within four weeks following completion. As the transaction has completed, Endeavor DNA, Inc. will operate the businesses on and from Saturday, 18 January 2025. | 20/01/2025 |
The company is set to sell its Direct-to-Consumer businesses and assets, including brands like EasyDNA, AffinityDNA, GTLDNA, HomeDNADirect, and International Biosciences, through an Asset Sale Agreement. | 15/01/2025 |
The company has completed the sale of its geneTypeTM business and assets to Rhythm Biosciences Limited, ensuring a smooth transition and satisfaction of conditions precedent. | 24/12/2024 |
Rhythm Biosciences Ltd has entered into an Asset Sale Agreement with Genetic Technologies Ltd for the acquisition of select assets related to the Genetype business. | 23/12/2024 |
The Administrators issued a Report to Creditors on 13 December 2024, announcing the second meeting of creditors for the Company. The meeting is scheduled for 20 December 2024 via videoconference and will be adjourned for up to 45 business days. The Administrators aim to reconvene the meeting earlier than 45 days and provide creditors with 5 business days' notice. | 13/12/2024 |
The company has received a Delisting Notice from Nasdaq Stock Market LLC due to the appointment of Voluntary Administrators. The company's American Depository Shares will be suspended from trading on 17 December 2024, and a Form 25-NSE will be filed with the SEC. Nasdaq cited public interest concerns, residual equity interest, and compliance with Nasdaq Listing Rule 5550(b). | 13/12/2024 |
The company plans to rely on the ASIC Corporations Instrument 2015/251, which allows for the deferral of financial reporting obligations for a minimum of 6 months and up to a maximum of 24 months. During the deferral period, GTG is not required to comply with any obligations under Part 2M.3 of the Corporations Act, and its Annual General Meeting is deferred until at least 2 months after the financial reporting relief ceases. | 02/12/2024 |
The company lodges a response to an ASX Query. | 29/11/2024 |
The Company offered shareholders a 2 for 3 rights issue to raise $2 million to $3.88 million, intended for working capital and operational transition. Administrators approved the withdrawal of the Offer, closing all offers, avoiding securities issues, and refunding all funds. | 26/11/2024 |
The company's securities were suspended on October 21, 2024, pending an announcement about an entitlement offer and strategic distribution partnership. Following the appointment of voluntary administrators, the suspension will continue until ASX confirms compliance with Listing Rules. | 22/11/2024 |
Ross Blakeley and Paul Harlond were appointed as Joint and Several Voluntary Administrators effective 20 November 2024. | 20/11/2024 |
The company has extended the closing date of all offers under the Entitlement Offer Prospectus to 2 December 2024. The company also extended the voluntary suspension of its securities until the commencement of trade or an earlier market announcement. The suspension is necessary for finalizing funding, securing distribution partnerships, investment, and minimum orders. | 01/11/2024 |
The company releases its Quarterly Activities/Appendix 4C Cash Flow Report. | 31/10/2024 |
The company has extended its voluntary suspension of its securities until the commencement of trade on 4 November 2024. The suspension was granted due to the need for additional time to finalize agreements, secure funding, and secure distribution partnerships. | 24/10/2024 |
The securities of Genetic Technologies Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GTG, pending the release of an announcement regarding an entitlement offer and a strategic distribution partnership. | 21/10/2024 |
The following ordinary fully paid deferred shares of Genetic Technologies Limited will be suspended from quotation immediately under Listing Rule 17.3, due to the minimum subscription condition under the Non-Renounceable Entitlement Offer not having been meet: Security class code GTGN. | 16/09/2024 |
The suspension of trading in the securities of Genetic Technologies Limited will be lifted immediately, following the release by GTG of an announcement regarding a breach of Chapter 10 of the Listing Rules. | 06/08/2019 |
The company provides an operational update on its blockchain activities. In relation to the framework agreement between BCG and GTG, to date, no shares have been issued under the framework agreement and no milestones specified have been achiebed. The share price of GTG needs to reach and remain at a minimum of 2.5c prior to any milestone shares being issued. Any rights to the 486,000,000 milestone shares upon achievement of milestones lapse between 27 December 2019 and 27 June 2020. Also, the Blockshine Health joint venture agreement was terminated on 6 August 2019. Regarding project Shivom which was signed on 2 March 2018, the parties have not progressed further with the undertakings contained in the agreement in recent times. GTG is yet to receive any formal requests for resources or further input or consideration into any blockchain based projects, whether that be via the previous Blockshine Health Joint Venture, BCG or from any other party. As such, GTG intends to remain focused on its core genetic testing business activities and are not currently considering any blockchain related projects. There is no present intention of the Board to change its composition. | 06/08/2019 |
ASX suspended the company for breach of Listing 10.1 and required the company to take corrective action. One form of corrective action was to cancel the transaction. The JV agreement has been terminated effective 6 August 2019. GTG did not receive any formal requests for resources or further input or consideration into any blockchain based projects via the Blockshine Health Joint Venture. As such, GTG has been very focused on its core genetic testing business activities this past calendar year and considers termination of the JV agreement will have no material adverse impact on company operations. | 06/08/2019 |
The securities of Genetic Technologies Limited will be suspended from quotation immediately under Listing Rule 17.3, pending an announcement regarding a breach of Chapter 10 of the Listing Rules. | 02/08/2019 |
The securities of Genetic Technologies Limited will be reinstated to quotation immediately, following the release of an announcement by the Company. | 15/02/2018 |
The company has entered into a non-binding terms sheet with Blockchain Global. In addition, in order to secure additional working capital, the Company has also mandated Lodge Corporate Pty Ltd to assist in a proposed private placement of up to 324.7 million new GTG fully paid ordinary shares at an issue price of 0.014c per GTG share. | 15/02/2018 |
The company is presently in discussions with ASX regarding the possible application of ASX Listing Rule 11.1; its structure / operations in compliance with ASX Listing Rule 12.5 and whether a strategic alliance with Blockchain Global Ltd to explore the application of Blockchain technology to provide efficiencies and new opportunities leveraging off the GTG existing genomics business would result in a change of activities of GTG. While these discussions are continuing, the ASX has required that GTG continue in suspension. | 12/02/2018 |
The securities of Genetic Technologies Limited will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company. | 31/01/2018 |
The suspension of trading in the securities of Genetic Technologies Limited will be lifted immediately following the release of an announcement regarding restructuring plans and finalisation of funding. ASX Code: GTG | 15/09/2014 |
The securities of Genetic Technologies Limited (the "Company") will be suspended from quotation immediately at the request of the Company pending the release of an announcement. Security Code: GTG | 11/09/2014 |
securities reinstated | 22/07/2011 |
Genetic Technologies now expects that the capital raising will be finalised on 22 July 2011 (AEST), when a further announcement is expected to be made by the Company in compliance with the ASX listing rules, and at which time the Company expects to recommence trading on both the ASX and NASDAQ | 20/07/2011 |
securities suspended pending an announcement | 13/07/2011 |
Geoffrey Edgar Newing, 44, of Hawthorn East, Victoria, is sentenced to a total of 22 months imprisonment and was ordered to serve six months of this sentence before being released on a recognisance release order | 18/03/2010 |
former Genetic Technologies Limited (GTG) chief operating officer, Geoffrey Edgar Newing, today pleaded guilty to five counts of market manipulation in the Melbourne Magistrates' Court, following an investigation by ASIC - the charges relate to Mr Newing's involvement in the trading of GTG shares between 16 May 2006 and 7 August 2006 - ASIC alleges that during this period Mr Newing took part in transactions involving purchases of more than 2,500,000 GTG shares through a share trading account held in the name of his related company, Palamine Pty Ltd. These transactions, according to ASIC, were likely to create or maintain an artificial price for trading in GTG shares | 25/01/2010 |
name changed from Duketon Goldfields Limited | 04/09/2000 |
The company's Voluntary Administrators have called a reconvened second creditors' meeting on 12 February 2025. The meeting will decide whether to execute a DOCA, end administration, or wind up the company. The Administrators believe it is in creditors' interests. | 05/02/2025 |
The entities suspended for over three months failed periodic reports, the oldest outstanding report deadline, and their 2 year deadline for trading plans. If not met, they will be removed from the official list, usually after the first trading day. | 22/01/2025 |
On 15 January 2025, Genetic Technologies Limited entered into a conditional agreement to sell its direct to consumer AffinityDNA and EasyDNA businesses to Endeavor DNA, Inc. On Saturday, 18 January 2025 the sale of the AffinityDNA and EasyDNA businesses completed. GTG has also granted Endeavor an option to purchase two of its subsidiaries that employ persons involved in conducting the businesses, exercisable by Endeavor within four weeks following completion. As the transaction has completed, Endeavor DNA, Inc. will operate the businesses on and from Saturday, 18 January 2025. | 20/01/2025 |
The company is set to sell its Direct-to-Consumer businesses and assets, including brands like EasyDNA, AffinityDNA, GTLDNA, HomeDNADirect, and International Biosciences, through an Asset Sale Agreement. | 15/01/2025 |
The company has completed the sale of its geneTypeTM business and assets to Rhythm Biosciences Limited, ensuring a smooth transition and satisfaction of conditions precedent. | 24/12/2024 |
Rhythm Biosciences Ltd has entered into an Asset Sale Agreement with Genetic Technologies Ltd for the acquisition of select assets related to the Genetype business. | 23/12/2024 |
The Administrators issued a Report to Creditors on 13 December 2024, announcing the second meeting of creditors for the Company. The meeting is scheduled for 20 December 2024 via videoconference and will be adjourned for up to 45 business days. The Administrators aim to reconvene the meeting earlier than 45 days and provide creditors with 5 business days' notice. | 13/12/2024 |
The company has received a Delisting Notice from Nasdaq Stock Market LLC due to the appointment of Voluntary Administrators. The company's American Depository Shares will be suspended from trading on 17 December 2024, and a Form 25-NSE will be filed with the SEC. Nasdaq cited public interest concerns, residual equity interest, and compliance with Nasdaq Listing Rule 5550(b). | 13/12/2024 |
The company plans to rely on the ASIC Corporations Instrument 2015/251, which allows for the deferral of financial reporting obligations for a minimum of 6 months and up to a maximum of 24 months. During the deferral period, GTG is not required to comply with any obligations under Part 2M.3 of the Corporations Act, and its Annual General Meeting is deferred until at least 2 months after the financial reporting relief ceases. | 02/12/2024 |
The company lodges a response to an ASX Query. | 29/11/2024 |
The Company offered shareholders a 2 for 3 rights issue to raise $2 million to $3.88 million, intended for working capital and operational transition. Administrators approved the withdrawal of the Offer, closing all offers, avoiding securities issues, and refunding all funds. | 26/11/2024 |
The company's securities were suspended on October 21, 2024, pending an announcement about an entitlement offer and strategic distribution partnership. Following the appointment of voluntary administrators, the suspension will continue until ASX confirms compliance with Listing Rules. | 22/11/2024 |
Ross Blakeley and Paul Harlond were appointed as Joint and Several Voluntary Administrators effective 20 November 2024. | 20/11/2024 |
The company has extended the closing date of all offers under the Entitlement Offer Prospectus to 2 December 2024. The company also extended the voluntary suspension of its securities until the commencement of trade or an earlier market announcement. The suspension is necessary for finalizing funding, securing distribution partnerships, investment, and minimum orders. | 01/11/2024 |
The company releases its Quarterly Activities/Appendix 4C Cash Flow Report. | 31/10/2024 |
The company has extended its voluntary suspension of its securities until the commencement of trade on 4 November 2024. The suspension was granted due to the need for additional time to finalize agreements, secure funding, and secure distribution partnerships. | 24/10/2024 |
The securities of Genetic Technologies Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GTG, pending the release of an announcement regarding an entitlement offer and a strategic distribution partnership. | 21/10/2024 |
The following ordinary fully paid deferred shares of Genetic Technologies Limited will be suspended from quotation immediately under Listing Rule 17.3, due to the minimum subscription condition under the Non-Renounceable Entitlement Offer not having been meet: Security class code GTGN. | 16/09/2024 |
The suspension of trading in the securities of Genetic Technologies Limited will be lifted immediately, following the release by GTG of an announcement regarding a breach of Chapter 10 of the Listing Rules. | 06/08/2019 |
The company provides an operational update on its blockchain activities. In relation to the framework agreement between BCG and GTG, to date, no shares have been issued under the framework agreement and no milestones specified have been achiebed. The share price of GTG needs to reach and remain at a minimum of 2.5c prior to any milestone shares being issued. Any rights to the 486,000,000 milestone shares upon achievement of milestones lapse between 27 December 2019 and 27 June 2020. Also, the Blockshine Health joint venture agreement was terminated on 6 August 2019. Regarding project Shivom which was signed on 2 March 2018, the parties have not progressed further with the undertakings contained in the agreement in recent times. GTG is yet to receive any formal requests for resources or further input or consideration into any blockchain based projects, whether that be via the previous Blockshine Health Joint Venture, BCG or from any other party. As such, GTG intends to remain focused on its core genetic testing business activities and are not currently considering any blockchain related projects. There is no present intention of the Board to change its composition. | 06/08/2019 |
ASX suspended the company for breach of Listing 10.1 and required the company to take corrective action. One form of corrective action was to cancel the transaction. The JV agreement has been terminated effective 6 August 2019. GTG did not receive any formal requests for resources or further input or consideration into any blockchain based projects via the Blockshine Health Joint Venture. As such, GTG has been very focused on its core genetic testing business activities this past calendar year and considers termination of the JV agreement will have no material adverse impact on company operations. | 06/08/2019 |
The securities of Genetic Technologies Limited will be suspended from quotation immediately under Listing Rule 17.3, pending an announcement regarding a breach of Chapter 10 of the Listing Rules. | 02/08/2019 |
The securities of Genetic Technologies Limited will be reinstated to quotation immediately, following the release of an announcement by the Company. | 15/02/2018 |
The company has entered into a non-binding terms sheet with Blockchain Global. In addition, in order to secure additional working capital, the Company has also mandated Lodge Corporate Pty Ltd to assist in a proposed private placement of up to 324.7 million new GTG fully paid ordinary shares at an issue price of 0.014c per GTG share. | 15/02/2018 |
The company is presently in discussions with ASX regarding the possible application of ASX Listing Rule 11.1; its structure / operations in compliance with ASX Listing Rule 12.5 and whether a strategic alliance with Blockchain Global Ltd to explore the application of Blockchain technology to provide efficiencies and new opportunities leveraging off the GTG existing genomics business would result in a change of activities of GTG. While these discussions are continuing, the ASX has required that GTG continue in suspension. | 12/02/2018 |
The securities of Genetic Technologies Limited will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company. | 31/01/2018 |
The suspension of trading in the securities of Genetic Technologies Limited will be lifted immediately following the release of an announcement regarding restructuring plans and finalisation of funding. ASX Code: GTG | 15/09/2014 |
The securities of Genetic Technologies Limited (the "Company") will be suspended from quotation immediately at the request of the Company pending the release of an announcement. Security Code: GTG | 11/09/2014 |
securities reinstated | 22/07/2011 |
Genetic Technologies now expects that the capital raising will be finalised on 22 July 2011 (AEST), when a further announcement is expected to be made by the Company in compliance with the ASX listing rules, and at which time the Company expects to recommence trading on both the ASX and NASDAQ | 20/07/2011 |
securities suspended pending an announcement | 13/07/2011 |
Geoffrey Edgar Newing, 44, of Hawthorn East, Victoria, is sentenced to a total of 22 months imprisonment and was ordered to serve six months of this sentence before being released on a recognisance release order | 18/03/2010 |
former Genetic Technologies Limited (GTG) chief operating officer, Geoffrey Edgar Newing, today pleaded guilty to five counts of market manipulation in the Melbourne Magistrates' Court, following an investigation by ASIC - the charges relate to Mr Newing's involvement in the trading of GTG shares between 16 May 2006 and 7 August 2006 - ASIC alleges that during this period Mr Newing took part in transactions involving purchases of more than 2,500,000 GTG shares through a share trading account held in the name of his related company, Palamine Pty Ltd. These transactions, according to ASIC, were likely to create or maintain an artificial price for trading in GTG shares | 25/01/2010 |
name changed from Duketon Goldfields Limited | 04/09/2000 |
Your browser may reflect a date of printing in American format.
DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
---|---|---|---|---|
06/03/2024 | Peter Rubenstein | 617,209 | $0.130 | $80,315 |
30/01/2023 | Jerzy Muchnicki | -38,400,000 | $0.873 | $33,539,328 |
02/06/2020 | Lindsay Wakefield | 1,092,841 | $0.006 | $6,284 |
02/06/2020 | Nick Burrows | 1,670,000 | $0.006 | $10,020 |
29/05/2020 | Peter Rubenstein | 60,000,000 | $0.005 | $314,960 |
NAME | TITLE | DATE OF APPT |
---|---|---|
Peter Rubenstein | Chairman | 31/01/2018 |
Simon Morriss | CEO | 01/02/2021 |
Mark Ziirsen | CFO, Company Secretary | 16/07/2024 |
Lindsay Wakefield | Non Exec Director | 24/09/2014 |
Jerzy Muchnicki | Executive Director | 31/01/2018 |
Date of first appointment, title may have changed.
NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
---|---|---|---|
Kathryn Andrews | CFO, Company Secretary | 25/03/2024 | 28/06/2024 |
Tony Di Pietro | CFO | 10/10/2022 | 31/03/2024 |
Nick Burrows | Non Exec Director | 02/09/2019 | 15/02/2024 |
Michael Tonroe | CFO | 28/06/2021 | 30/11/2022 |
Stan Sack | COO | 18/05/2020 | 30/04/2022 |
Phillip Hains | CFO | 15/07/2019 | 15/06/2021 |
Paul Kasian | Chairman, CEO | 12/12/2013 | 24/09/2019 |
Paul Viney | CFO, COO | 27/12/2018 | 15/07/2019 |
Sam Lee | Non Exec Director | 31/01/2018 | 09/07/2019 |
Kevin Fisher | CFO | 02/11/2015 | 31/12/2018 |
Eutillio Buccilli | Director, CEO | 02/06/2014 | 06/02/2018 |
Malcolm Brandon | Non Exec Chairman | 05/10/2009 | 30/01/2018 |
Grahame Leonard | Non Exec Director | 29/11/2013 | 30/01/2018 |
Susan Gross | Director | 20/06/2016 | 15/09/2017 |
Brian Manuel | CFO | 15/06/2015 | 02/11/2015 |
David Carter | Non Exec Director | 24/09/2014 | 29/01/2015 |
Alison Mew | CEO | 31/08/2009 | 31/12/2014 |
Ian McKenzie | Non Exec Director | 29/11/2013 | 29/11/2014 |
Mervyn Cass | Non Exec Director | 30/09/2011 | 27/11/2014 |
Tom Howitt | CFO, Deputy CEO | 01/06/2004 | 28/03/2014 |
Tom Bonvino | Non Exec Director | 25/11/2009 | 29/11/2013 |
Ben Silluzio | Non Exec Director | 10/12/2012 | 29/11/2013 |
Melvyn Bridges | Chairman, Non Exec Director | 16/12/2011 | 27/11/2012 |
Paul MacLeman | CEO | 04/05/2009 | 27/11/2012 |
Gregory Brown | Non Exec Director | 24/07/2012 | 27/11/2012 |
Huw Jones | Director | 20/11/2008 | 27/11/2012 |
Sidney Hack | Non Exec Director | 19/11/2008 | 18/12/2011 |
Fred Bart | Non Exec Chairman | 25/10/1996 | 26/11/2009 |
Mervyn Jacobson | Non Exec Director | 15/05/2020 | 14/12/2008 |
Henry Bosch | Non Exec Chairman | 24/06/2005 | 21/11/2008 |
Michael Ohanessian | CEO | 24/09/2007 | 21/11/2008 |
David Carruthers | Non Exec Director | 26/02/2007 | 21/11/2008 |
John Dawkins | Non Exec Director | 24/11/2004 | 21/11/2008 |
Leanne Rowe | Non Exec Director | 16/04/2008 | 21/11/2008 |
Robert Edge | Non Exec Director | 19/04/2004 | 19/11/2006 |
Ian Dennis | Executive Director | 24/11/1994 | 26/11/2004 |
Russell Granzow | Executive Director | 06/05/2003 | 21/04/2004 |
Ian Gust | Non Exec Director | 26/04/2001 | 02/12/2001 |
Peter Vassilieff | Non Exec Director | 28/04/2001 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.